LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Lee, Hans C.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Hoffman, James E.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Shah, Mansi R.
Lentzsch, Suzanne
Maly, Joseph J.
Ye, Jing Christine
Wu, Ka Lung
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Jagannath, Sundar
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Univ Miami Hlth Syst, Miami, FL USA
[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[7] Roudebush VAMC, Indianapolis, IN USA
[8] Karmanos Canc Inst, Detroit, MI USA
[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[10] Columbia Univ, Med Ctr, New York, NY USA
[11] Norton Canc Inst, Louisville, KY USA
[12] Univ Michigan, Ann Arbor, MI USA
[13] Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
[14] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8006
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Lalo, Silvana
    Kruppa, Carrie
    Gardner, Diane
    Kennedy, Ryan C.
    Burt, Steve
    Mapara, Markus Y.
    Redner, Robert
    Roodman, David
    Volkin, Robert L.
    Zonder, Jeffrey
    BLOOD, 2009, 114 (22) : 736 - 736
  • [24] Non-myeloablative allogeneic transplantation in patients with relapsed or refractory multiple myeloma.
    Gerull, S
    Hegenbart, U
    Goerner, M
    Benner, A
    Moehler, T
    Goldschmidt, H
    Ho, AD
    BLOOD, 2004, 104 (11) : 755A - 755A
  • [25] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] PAD is a highly effective regimen for the treatment of patients with relapsed refractory multiple myeloma.
    Delforge, Michel
    Janssens, Ann
    Dierickx, Dann
    Maertens, Johan
    Theunissen, Koen
    Vandenberghe, Peter
    Verhoef, Gregor
    BLOOD, 2006, 108 (11) : 363B - 363B
  • [27] Weekly bortezomib with or without glucocorticosteroids is effective in patients with relapsed or refractory multiple myeloma.
    Suvannasankha, A
    Smith, GG
    Abonour, R
    BLOOD, 2005, 106 (11) : 720A - 720A
  • [28] Clinical study of fludarabine, mitoxantrone, and dexamethasone in the treatment of refractory or relapsed multiple myeloma.
    Luo, SK
    Li, J
    Hong, WD
    Zhao, Y
    Tong, XZ
    BLOOD, 2005, 106 (11) : 380B - 380B
  • [29] A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Nefedova, Yulia
    Wileyto, E. Paul
    Sembhi, Harjeet
    Strakovsky, Inna
    Nguyen, Chau
    Taneja, Rimzim
    Bondesson, Eva
    Eriksson, Helena
    Tuvesson, Helen
    BLOOD, 2020, 136
  • [30] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345